Ascent Group, LLC Gilead Sciences, Inc. Transaction History

Ascent Group, LLC

$1.21 Billion
Q2 2024

A detailed history of Ascent Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ascent Group, LLC holds 12,860 shares of GILD stock, worth $1.09 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

12,860

Previous 15,142 15.07%

Holding current value

$1.09 Million

Previous $1.11 Million 20.47%

% of portfolio

0.07%

Previous 0.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $144,108 - $166,312	-2,282 Reduced 15.07%	12,860 $882,000
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $101,715 - $124,039	-1,421 Reduced 8.58%	15,142 $1.11 Million
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $1.9 Million - $2.15 Million	-25,915 Reduced 61.01%	16,563 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $188,916 - $206,111	2,555 Added 6.4%	42,478 $3.18 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $82,166 - $93,722	-1,081 Reduced 2.64%	39,923 $3.08 Million
Q1 2023 May 10, 2023	SELL	$77.31 - $88.08 $551,452 - $628,274	-7,133 Reduced 14.82%	41,004 $3.4 Million
Q4 2022 Feb 16, 2023	BUY	$62.32 - $89.47 $184,903 - $265,457	2,967 Added 6.57%	48,137 $4.13 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.13 Million - $1.29 Million	18,907 Added 71.99%	45,170 $3.54 Million
Q2 2022 Aug 05, 2022	BUY	$57.72 - $65.01 $756,997 - $852,606	13,115 Added 99.75%	26,263 $1.57 Million
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $378,043 - $473,729	6,527 Added 98.58%	13,148 $782,000
Q4 2021 Mar 01, 2022	BUY	$64.88 - $73.64 $429,570 - $487,570	6,621 New	6,621 $454,000

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $106B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ascent Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ascent Group, LLC with notifications on news.

Account